US-based pharmaceutical company Merck & Co has recalled Liptruzet products from wholesalers in the domestic market due to a defect in the product's packaging.
The defective outer laminated foil pouches are liable to allow air and moisture into the package reducing effectiveness of the drug used in lowering cholesterol levels.
According to the company, the possibility of package defects that could have an impact on the products is rare.
Under the recall, the firm will drain all available supply of Liptruzet in the country as well as in Puerto Rico, while allowing the active ingredient Zetia to be available.
Merck is not recalling the medicines from pharmacies or patients and is working with the US Food and Drug Administration for the recall process.
The company claims to have not received any complaints or reports regarding the Liptruzet defects.